SE0101697D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0101697D0
SE0101697D0 SE0101697A SE0101697A SE0101697D0 SE 0101697 D0 SE0101697 D0 SE 0101697D0 SE 0101697 A SE0101697 A SE 0101697A SE 0101697 A SE0101697 A SE 0101697A SE 0101697 D0 SE0101697 D0 SE 0101697D0
Authority
SE
Sweden
Prior art keywords
androgen
relates
erbeta
optionally
pharmaceutical product
Prior art date
Application number
SE0101697A
Other languages
English (en)
Swedish (sv)
Inventor
Nigel Brooks
Barry Furr
Chris Veale
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101697A priority Critical patent/SE0101697D0/xx
Publication of SE0101697D0 publication Critical patent/SE0101697D0/xx
Priority to PCT/GB2002/002125 priority patent/WO2002092129A2/en
Priority to AU2002302737A priority patent/AU2002302737A1/en
Priority to EP02730415A priority patent/EP1395286A2/de
Priority to JP2002589045A priority patent/JP2004529182A/ja
Priority to US10/477,242 priority patent/US20040204390A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0101697A 2001-05-14 2001-05-14 Pharmaceutical combination SE0101697D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0101697A SE0101697D0 (sv) 2001-05-14 2001-05-14 Pharmaceutical combination
PCT/GB2002/002125 WO2002092129A2 (en) 2001-05-14 2002-05-08 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
AU2002302737A AU2002302737A1 (en) 2001-05-14 2002-05-08 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
EP02730415A EP1395286A2 (de) 2001-05-14 2002-05-08 Pharmazeutisches kombinationspräparat enthaltend einen antiandrogen- und einen oestrogen-rezeptor beta- agonisten
JP2002589045A JP2004529182A (ja) 2001-05-14 2002-05-08 医薬組成物
US10/477,242 US20040204390A1 (en) 2001-05-14 2002-05-08 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101697A SE0101697D0 (sv) 2001-05-14 2001-05-14 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0101697D0 true SE0101697D0 (sv) 2001-05-14

Family

ID=20284106

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101697A SE0101697D0 (sv) 2001-05-14 2001-05-14 Pharmaceutical combination

Country Status (6)

Country Link
US (1) US20040204390A1 (de)
EP (1) EP1395286A2 (de)
JP (1) JP2004529182A (de)
AU (1) AU2002302737A1 (de)
SE (1) SE0101697D0 (de)
WO (1) WO2002092129A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP3696276A1 (de) * 2013-02-25 2020-08-19 Novartis AG Neuartige androgenrezeptormutation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
AU7165798A (en) * 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
CA2299471C (en) * 1997-08-15 2007-12-18 Cephalon Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
JP3270030B2 (ja) * 1999-10-12 2002-04-02 株式会社ファンケル 食品組成物
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment

Also Published As

Publication number Publication date
WO2002092129A3 (en) 2003-02-27
AU2002302737A1 (en) 2002-11-25
JP2004529182A (ja) 2004-09-24
US20040204390A1 (en) 2004-10-14
WO2002092129A2 (en) 2002-11-21
EP1395286A2 (de) 2004-03-10

Similar Documents

Publication Publication Date Title
ATE420083T1 (de) Harnstoff-derivate als vanilloid-rezeptor- antagonisten für die schmerzbehandlung
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
EP1610751A4 (de) Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
SE0100568D0 (sv) Compounds
EP1364703A4 (de) "aktive struktur, vorrichtung zur aktivierung eines stoffes und verfahren zur aktivierung eines stoffes"
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
CY1110521T1 (el) Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
EP1423107A4 (de) Fettalkohol-arzneimittel-konjugate
IT1318425B1 (it) Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
MY137435A (en) Retinoid compounds (i)
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
PT1432417E (pt) Compostos de benzimidazole substituído e sua utilização para o tratamento de cancro
SE0100566D0 (sv) Compounds
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
SE0101697D0 (sv) Pharmaceutical combination
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
DE60226319D1 (de) Verbindungen die ein an einen vektor gebundenes analgetisches molekül enthalten
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
SE0101692D0 (sv) Compounds
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling